Currently, dopaminomimetics and monoamine oxidase B (MAO-B) inhibitors are utilized to suppress dopamine decomposition in PD therapy, nevertheless, they simply treat symptoms and have severe side effects [1]
They may recommend supplements and can advise on the dosage
(4) When encapsulated in liposomes, GHK-Cu peptide apparently better supported VEGF and FGF-2 expression to a greater degree than the free peptide, with both growth factors reportedly increasing more than twofold relative to controls
doi:10.1016/j.febslet.2007.06.049 208
No regulatory authority Health Canada, the FDA, the EMA, the TGA, or any equivalent has cleared BPC-157 for therapeutic use in humans or animals
Ramipril-treated individuals had more normoglycemia relapses